正常血压和高血压受试者钠-锂逆向转运的动力学
Kinetics of sodium-lithium countertransport in normotensive and hypertensive subjects.
作者信息
Siebers R W, Maling T J
机构信息
Department of Medicine, Wellington School of Medicine, New Zealand.
出版信息
J Cardiovasc Pharmacol. 1990;16 Suppl 7:S59-61.
The kinetic parameters Vmax and Km of erythrocyte sodium-lithium countertransport (Na-Li CT), and the lithium cell to plasma ratio (Li C:P) measured 24 h after a 1-g oral dose of Li2CO3, were determined in 14 normotensive (NT) and 14 untreated mild hypertensive (HT) males matched for age and weight. Li C:P and Na-Li CT were strongly correlated (r = -0.73), p less than 0.001), confirming the validity of Li C:P as an in vivo index of Na-Li CT. No differences in Li C:P (NT: 0.27 +/- 0.07; HT: 0.23 +/- 0.06), Na-Li CT (NT: 0.39 +/- 0.10 mmol/L/h; HT: 0.43 +/- 0.10 mmol/L/h), Vmax (NT: 0.58 +/- 0.16 mmol/L/h; HT: 0.68 +/- 0.20 mmol/L/h), or Km (NT: 1.5 +/- 0.4 mmol/L; HT: 1.6 +/- 0.9 mmol/L) were found between NT and HT. Our data do not support the marker concept of erythrocyte Na-Li CT in human hypertension.
在14名年龄和体重匹配的正常血压（NT）男性和14名未经治疗的轻度高血压（HT）男性中，测定了口服1克碳酸锂24小时后红细胞钠-锂逆向转运（Na-Li CT）的动力学参数Vmax和Km，以及锂细胞与血浆比值（Li C:P）。Li C:P与Na-Li CT高度相关（r = -0.73，p < 0.001），证实了Li C:P作为Na-Li CT体内指标的有效性。NT组和HT组在Li C:P（NT：0.27±0.07；HT：0.23±0.06）、Na-Li CT（NT：0.39±0.10 mmol/L/h；HT：0.43±0.10 mmol/L/h）、Vmax（NT：0.58±0.16 mmol/L/h；HT：0.68±0.20 mmol/L/h）或Km（NT：1.5±0.4 mmol/L；HT：1.6±0.9 mmol/L）方面均未发现差异。我们的数据不支持红细胞Na-Li CT在人类高血压中的标志物概念。
Zotero 插件